Elamipretide (SS-31 and Forzinity)

FDA approved Forzinity to improve muscle strength in patients with Barth syndrome weighing at least 30 kilograms. Approval was based on improved knee extensor strength, an intermediate clinical endpoint. Continued approval may depend on confirmatory trials verifying clinical benefit. The narrowly defined indication should not be rewritten as proof of benefit in healthy aging. ^{1, 2}

Injection-site reactions are prominent adverse effects. Serious hypersensitivity reactions require attention, and the label contains population- and formulation-specific precautions. The full product information, not a research-vial name, is the relevant starting point for a prescribing discussion. ²

A research label does not establish pharmaceutical identity, approval, sterility or clinical suitability. An online product using the SS-31 name cannot borrow Forzinity’s evaluated manufacturing or clinical evidence. This reference does not describe a wellness protocol or verify dispensing availability.

Forzinity received accelerated approval based on improved knee extensor strength, an intermediate clinical endpoint. That pathway allows earlier access while confirmatory trials verify clinical benefit. It does not mean every proposed mitochondrial outcome was proven, and continued approval can depend on the required evidence. Patients and clinicians should follow the current Barth-syndrome label and updates rather than extrapolating from the approval headline to fatigue, exercise performance or healthy aging. ^{1, 2}

Forzinity is a defined subcutaneous prescription product for patients with Barth syndrome who meet the weight criterion. Storage, preparation, injection and missed-dose instructions belong to that product. Injection-site reactions are common, and severe hypersensitivity needs urgent care. A vial sold as SS-31, a compounded preparation or a research chemical may have different identity, purity, salt form and concentration. It does not inherit the approved product's manufacturing controls or clinical evidence. ^{1, 2}

Barth syndrome can involve heart disease, muscle weakness, growth problems and neutropenia, so elamipretide decisions sit within specialist care rather than a stand-alone energy treatment. Follow-up should connect muscle function and adverse effects with cardiac, blood-count and overall disease monitoring. New breathing difficulty, swelling, fainting, fever or infection symptoms require prompt assessment based on the individual's condition. Do not replace established cardiac or supportive treatment because an accelerated-approval medicine has been added. ^{1, 2}

Accelerated approval is still FDA approval for the labeled Forzinity use, but it carries an evidence obligation and a narrow population. It should be described neither as merely experimental for Barth syndrome nor as broad validation of mitochondrial therapy. The current label, required confirmatory work and specialist follow-up all matter. Regulatory status can be precise without overstating what the intermediate endpoint proves. ^{1, 2}